OliX Pharmaceuticals, Inc (KOSDAQ:226950)
South Korea · Delayed Price · Currency is KRW 186,900
+5,100 (2.81%)
At close: Mar 20, 2026
OliX Pharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,667 | 5,677 | 17,064 | 9,320 | 3,674 | |
Revenue Growth (YoY) | 158.35% | -66.73% | 83.09% | 153.66% | 48.50% |
Cost of Revenue | 332.99 | 248.67 | 159.88 | 206.95 | 171.77 |
Gross Profit | 14,334 | 5,428 | 16,904 | 9,113 | 3,503 |
Selling, General & Admin | 16,784 | 14,444 | 14,178 | 12,346 | 11,488 |
Research & Development | 25,647 | 19,536 | 18,478 | 17,379 | 14,992 |
Amortization of Goodwill & Intangibles | 47.67 | 48.96 | 46.05 | 40.75 | 163.02 |
Other Operating Expenses | 601.69 | 591.19 | 570.74 | 657.94 | 395.85 |
Operating Expenses | 44,306 | 36,347 | 35,090 | 31,489 | 27,731 |
Operating Income | -29,972 | -30,919 | -18,185 | -22,376 | -24,229 |
Interest Expense | -1,820 | -4,661 | -3,492 | -2,930 | -2,431 |
Interest & Investment Income | 1,118 | 538.05 | 1,286 | 1,396 | 476.04 |
Earnings From Equity Investments | - | -8,223 | -900.91 | - | - |
Currency Exchange Gain (Loss) | 360.65 | -386.18 | 14.62 | -127.59 | -23 |
Other Non Operating Income (Expenses) | 16,964 | 582.03 | 2,335 | -5,054 | -3,675 |
EBT Excluding Unusual Items | -13,349 | -43,069 | -18,943 | -29,092 | -29,881 |
Gain (Loss) on Sale of Investments | -76.72 | 349.21 | 438.97 | -36.12 | 11.17 |
Gain (Loss) on Sale of Assets | 256.32 | 1,649 | -87.48 | 20.34 | -416.83 |
Other Unusual Items | -82.59 | - | 421.58 | - | 289.29 |
Pretax Income | -13,252 | -41,071 | -18,170 | -29,108 | -29,997 |
Income Tax Expense | 2,491 | -411.97 | 932.07 | -994.9 | -821.54 |
Earnings From Continuing Operations | -15,743 | -40,659 | -19,102 | -28,113 | -29,176 |
Earnings From Discontinued Operations | - | - | - | 6,225 | -1,102 |
Net Income to Company | -15,743 | -40,659 | -19,102 | -21,888 | -30,278 |
Minority Interest in Earnings | - | - | - | 2,392 | 563.24 |
Net Income | -15,743 | -40,659 | -19,102 | -19,495 | -29,715 |
Net Income to Common | -15,743 | -40,659 | -19,102 | -19,495 | -29,715 |
Shares Outstanding (Basic) | 20 | 17 | 14 | 14 | 14 |
Shares Outstanding (Diluted) | 20 | 17 | 14 | 14 | 14 |
Shares Change (YoY) | 16.84% | 16.73% | 5.30% | 0.13% | 4.06% |
EPS (Basic) | -800.00 | -2414.00 | -1323.81 | -1422.69 | -2171.18 |
EPS (Diluted) | -800.00 | -2414.00 | -1324.00 | -1422.69 | -2171.18 |
Free Cash Flow | -17,161 | -41,510 | -29,995 | -32,916 | -20,344 |
Free Cash Flow Per Share | -872.10 | -2464.53 | -2078.73 | -2402.08 | -1486.45 |
Gross Margin | 97.73% | 95.62% | 99.06% | 97.78% | 95.33% |
Operating Margin | -204.36% | -544.62% | -106.57% | -240.07% | -659.40% |
Profit Margin | -107.34% | -716.18% | -111.94% | -209.17% | -808.70% |
Free Cash Flow Margin | -117.01% | -731.17% | -175.77% | -353.16% | -553.66% |
EBITDA | -27,519 | -28,292 | -15,543 | -20,301 | -22,599 |
EBITDA Margin | -187.63% | - | -91.09% | -217.81% | - |
D&A For EBITDA | 2,454 | 2,626 | 2,642 | 2,075 | 1,630 |
EBIT | -29,972 | -30,919 | -18,185 | -22,376 | -24,229 |
EBIT Margin | -204.36% | - | -106.57% | -240.07% | - |
Advertising Expenses | 195.26 | 58 | 77.82 | 73.74 | 63.88 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.